In the FIGHT [80] and LIVE [81] RCTs performed in patients with HF and reduced ejection fraction with and without T2DM, liraglutide treatment, compared to placebo, did not demonstrate a beneficial effect on left ventricular function, with a trend towards harm [80, 81]
Since its initial approval, the Food and Drug Administration (FDA) has approved two additional indications: to reduce the risk of adverse cardiovascular events in adults with Type 2 diabetes and heart disease and to reduce worsening of kidney disease in adults with Type 2 diabetes and chronic kidney disease
Stack Rationale: The combination may offer complementary mechanismssystemic repair signaling (TB-500) plus localized tissue healing (BPC-157)
They may also have different approved uses, such as chronic weight management or type 2 diabetes, depending on the product
instead, its best used to target specific concerns
Improves complexion, eliminates dullness and restores healthy glow